Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Predicted sensitivity to ET (SET2,3 index): results of an analysis of the SWOG S8814 trial

Corey Speers • 9 Dec 2021
SABCS 2021
Breast Cancer 5-fluorouracil Cyclophosphamide Doxorubicin
SWOG S8814

The SWOG trial S8814 (NCT00929591) randomized postmenopausal patients with pathologic lymph node-positive HR+ breast cancer to receive adjuvant anthracycline-based chemotherapy followed by tamoxifen endocrine therapy for 5 years, versus tamoxifen alonel the 2-gene Breast Recurence Score assay was determined to predict chemotherapy benefit in patients with a higher Recurrence Score. In this interview, Corey Speers, MD, PhD, University of Michigan Medicine, Ann Arbor, MI, discusses the results of an analysis of SWOG S8814 which evaluated the predicted sensitivity to endocrine therapy (ET) (SET2,3) index. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

More from Corey Speers

Radiation response as a biomarker for adjuvant breast cancer therapy
1:56
Radiation response as a biomarker for adjuvant breast cancer therapy
Corey Speers • 1 Jun 2026
Expanding the clinical use of multimodal AI in breast cancer care
1:38
Expanding the clinical use of multimodal AI in breast cancer care
Corey Speers • 1 Jun 2026
MMAI model validation for chemotherapy benefit prediction in breast cancer
1:58
MMAI model validation for chemotherapy benefit prediction in breast cancer
Corey Speers • 1 Jun 2026
Endocrine therapy treatment radiosensitizes ER+ breast cancer
1:11
Endocrine therapy treatment radiosensitizes ER+ breast cancer
Corey Speers • 9 Dec 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals